Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,772,256
  • Shares Outstanding, K 2,472,392
  • Annual Sales, $ 65,011 M
  • Annual Income, $ 18,254 M
  • EBIT $ 22,107 M
  • EBITDA $ 27,945 M
  • 60-Month Beta 0.27
  • Price/Sales 4.52
  • Price/Cash Flow 10.41
  • Price/Book 5.61

Options Overview Details

View History
  • Implied Volatility 34.24% (+1.59%)
  • Historical Volatility 22.12%
  • IV Percentile 80%
  • IV Rank 39.52%
  • IV High 53.48% on 04/10/25
  • IV Low 21.66% on 12/08/25
  • Expected Move (DTE 3) 3.45 (2.88%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 25,406
  • Volume Avg (30-Day) 54,379
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 518,577
  • Open Int (30-Day) 554,298
  • Expected Range 116.18 to 123.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.57
  • Number of Estimates 7
  • High Estimate 2.00
  • Low Estimate -1.63
  • Prior Year 2.22
  • Growth Rate Est. (year over year) -125.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.72 +6.13%
on 03/20/26
123.70 -3.29%
on 03/02/26
-4.19 (-3.38%)
since 02/27/26
3-Month
104.43 +14.56%
on 01/02/26
125.14 -4.40%
on 02/25/26
+12.85 (+12.03%)
since 12/26/25
52-Week
73.31 +63.18%
on 05/15/25
125.14 -4.40%
on 02/25/26
+32.03 (+36.56%)
since 03/27/25

Most Recent Stories

More News
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck’s WINREVAIR met primary endpoint of change in pulmonary vascular resistance (PVR), significantly improving the ability of blood to flow through the lungs to the heart ...

MRK : 119.63 (+0.59%)
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals...

MRK : 119.63 (+0.59%)
TERN : 52.92 (-0.47%)
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral  allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor...

MRK : 119.63 (+0.59%)
TERN : 52.92 (-0.47%)
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral  allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for certain patients with CML Merck to hold investor...

MRK : 119.63 (+0.59%)
TERN : 52.92 (-0.47%)
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML ...

MRK : 119.63 (+0.59%)
TERN : 52.92 (-0.47%)
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML ...

MRK : 119.63 (+0.59%)
TERN : 52.92 (-0.47%)
1 S&P 500 Stock to Target This Week and 2 We Ignore

1 S&P 500 Stock to Target This Week and 2 We Ignore

CVS : 70.08 (-1.55%)
PHM : 114.63 (-2.13%)
MRK : 119.63 (+0.59%)
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

Expanded label for once-yearly parasiticide treatment for dogs now includes Haemaphysalis longicornis (Asian longhorned tick) and Amblyomma maculatum (Gulf Coast...

MRK : 119.63 (+0.59%)
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026

Data show long-term effectiveness of GARDASIL ® 9 and GARDASIL ® 14 years and 18 years, respectively, following vaccination with 3 doses ...

MRK : 119.63 (+0.59%)
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research

Late-breaking presentation of results from the Phase 3 CORALreef AddOn trial evaluating enlicitide decanoate, Merck’s investigational oral PCSK9 inhibitor, which may help address the cardiovascular (CV)...

MRK : 119.63 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 123.40
2nd Resistance Point 122.24
1st Resistance Point 120.93
Last Price 119.63
1st Support Level 118.46
2nd Support Level 117.30
3rd Support Level 115.99

See More

52-Week High 125.14
Last Price 119.63
Fibonacci 61.8% 105.34
Fibonacci 50% 99.22
Fibonacci 38.2% 93.11
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.